Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 32348052!ä!32348052 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Med+Suisse 2020 ; 16 (N degrees 691-2): 852-854 Nephropedia Template TP {{tp|p=32348052|t=2020. Traitements aggravant une infection par le COVID-19 : vraiment ?|pdf=|usr=}}{{32348052}} gab.com Text Traitements aggravant une infection par le COVID-19 : vraiment JO: Rev Med Suisse http://www.kidney.de/pget.php?&tw=1&pmid=32348052 #FOAvip The safety of NSAIDs, corticosteroids and renin-angiotensin inhibitors in COVID-19 is challenged. NSAIDs may interfere with the defense process against viral infection and are best avoided. Systemic corticosteroids have not shown benefit in viral infection, including other coronavirus; thus they should be avoided, unless prescribed for another indication. The benefit-risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or COPD. ACE inhibitors and sartans upregulate the expression of angiotensin-converting enzyme 2 (ACE2), the pulmonary receptor for SARS-CoV-2. Any possible clinical impact of these treatments on COVID-19 infection remains to be clarified; in the meantime, they should be continued. Twit Text FOAVip Traitements aggravant une infection par le COVID-19 : vraiment ????Rev Med Suisse http://www.kidney.de/pget.php?&tw=1&pmid=32348052 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32348052 #FOAvip English Wikipedia <ref>{{Cite pmid|32348052}}</ref> Traitements aggravant une infection par le COVID-19 : vraiment ? #MMPMID32348052 Rothuizen LE; Livio F; Buclin T Rev Med Suisse 2020[Apr]; 16 (N degrees 691-2): 852-854 PMID32348052show ga The safety of NSAIDs, corticosteroids and renin-angiotensin inhibitors in COVID-19 is challenged. NSAIDs may interfere with the defense process against viral infection and are best avoided. Systemic corticosteroids have not shown benefit in viral infection, including other coronavirus; thus they should be avoided, unless prescribed for another indication. The benefit-risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or COPD. ACE inhibitors and sartans upregulate the expression of angiotensin-converting enzyme 2 (ACE2), the pulmonary receptor for SARS-CoV-2. Any possible clinical impact of these treatments on COVID-19 infection remains to be clarified; in the meantime, they should be continued. |*Adrenal Cortex Hormones/administration & dosage/adverse effects[MESH] |*Betacoronavirus[MESH] |*Coronavirus Infections/complications/epidemiology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/complications/epidemiology[MESH] |Angiotensin-Converting Enzyme Inhibitors/*administration & dosage[MESH] |Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects[MESH] |COVID-19[MESH] |Humans[MESH]Traitements aggravant une infection par le COVID-19 : vraiment ?(epmc).pdf DeepDyve Pubget Overpricing